SynVivo's Tissue on Chip Platform Advances Mechanistic Understanding of Sepsis - New Data Presented at 41st Annual SHOCK Conference

HUNTSVILLE, Ala., June 19, 2018 /PRNewswire-PRWeb/ -- Multiple studies presented at the 2018 SHOCK conference in Scottsdale AZ report on the use of SynVivo's 3D tissue chip models for inflammation and sepsis mediated vascular damage. Protein kinase C-delta (PKC?) was shown to be important regulator of neutrophil-endothelium interactions during inflammation and sepsis. Dr. Laurie Kilpatrick and Dr. Mohammad Kiani's research team at Temple University led this collaborative research study based on SynVivo's Blood Brain Barrier and Inflammation model. Fariborz Soroush, Ph.D. student in Dr. Kiani and Dr. Kilpatrick's laboratories also received the new investigator award for his work on regulation of the PKC? using the SynVivo platform.

Results of this multi-year NIH funded research project highlighted the novelty and uniquness of the platform for predicting in vivo observations in humans and rodents.

Data presented showed:

• In vitro replication of the in vivo microvascular networks, fluidic conditions and cell-cell interactions
• Effect of varying shear conditions on the leukocyte-endothelium interactions comprising of rolling, adhesion and migration
• Enhancement of vascular leakiness following sepsis mediated cytokine interactions by measurement of small molecule permeabilty across the endothelium.
• Identification of PKC? as an important regulator of neutrophil and endothelium interactions in both the brain and lung microvessels. A PKC? inhibitor was found to be a novel therapeutic to protect from sepsis mediated vascular damage.

"Using the SynVivo platform was instrumental in elucidating mechanisms by which PKC? regulates the inflammatory cascade," said Dr. Kilpatrick. "The real-time monitoring capability in the SynVivo platform provides us a novel method to mimic in vivo neutrophil-endothelium interactions."

"We are excited that the SynVivo platform was key to these important discoveries in inflammation and advances in sepsis therapy," said Kapil Pant, PhD., President and CEO of Synvivo Inc. "Our 3D tissue on chip models are important tools that can potentially accelerate drug discovery and the development of safer targeted drugs for sepsis and other challenging human diseases."

About SynVivo's Inflammation model
The SynRAMtm 3D Inflammation Model from SynVivo has been developed to study the entire inflammation pathway in a realistic and dynamic environment. By recreating a histological slice of co-cultured tissue and/or tumor cells with a lumen of endothelial cells, the SynVivo platform delivers a physiologically realistic model that has been successfully validated against in vivo studies.

About SynVivo Inc.
SynVivo® is a microfluidic tissue?organ on chip platform that provides a biologically realistic microenvironment allowing real-time study of cellular behavior and drug delivery. Additional information can be found by visiting

http://www.synvivobio.com
http://www.facebook.com/synvivobio
https://www.twitter.com/SynVivo

SOURCE SynVivo